<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574285</url>
  </required_header>
  <id_info>
    <org_study_id>DDS17-035BE</org_study_id>
    <nct_id>NCT03574285</nct_id>
  </id_info>
  <brief_title>A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions</brief_title>
  <official_title>A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl
      300mg Tablets Under Feeding Conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the bioequivalence of two formulations of Sarpogrelate HCl 300mg, Anpl-one SR
      Tab. 300mg (Reference) and generic Sarpogrelate HCl 300mg (Test), after a single oral dose
      administration in healthy Thai volunteers under feeding condition: open label, single-dose,
      randomized, two-period, two-treatment, two-sequence, crossover, comparative bioavailability
      study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Actual">October 12, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>0-24hr</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve</measure>
    <time_frame>0-24hr</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Anpl-one SR Tab. 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarpodipil SR Tab. 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anpl-one SR Tab. 300mg</intervention_name>
    <description>Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets</description>
    <arm_group_label>Anpl-one SR Tab. 300mg</arm_group_label>
    <arm_group_label>Sarpodipil SR Tab. 300mg</arm_group_label>
    <other_name>Sarpogrelate HCl 300mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpodipil SR Tab. 300mg</intervention_name>
    <description>Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets</description>
    <arm_group_label>Anpl-one SR Tab. 300mg</arm_group_label>
    <arm_group_label>Sarpodipil SR Tab. 300mg</arm_group_label>
    <other_name>Sarpogrelate HCl 300mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking, male and female subjects, 19 years of age or older

          -  BMI ≥ 18.0 and ≤ 30.0 kg/m2.

          -  Females who participate in this study will be of childbearing or non-childbearing
             potential

        Exclusion Criteria:

          -  Know history or presence of clinically significant neurologic, hematologic, endocrine,
             oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular
             disease or any other condition which, in the opinion of the investigator, would
             jeopardized the safety of the subject or impact the validity of the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Deawoong pharmaceutical</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06170</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

